Kibur Medical

Kibur Medical is a private Boston-based oncology technology company developing implantable microdevice-based diagnostics for precision cancer treatment and oncology drug development. Its core product, NanoNail, is a tumor-implanted, drug-eluting microdevice designed to expose a patient’s tumor to multiple drugs or drug combinations simultaneously and generate spatial, single-cell, multi-omic readouts of in vivo response. The company positions this platform both as a predictive diagnostic to help oncologists choose personalized therapies and as a translational research tool to help drug developers identify effective agents, combinations, and biomarkers earlier in development. Kibur has highlighted glioblastoma and other high-grade gliomas as an initial commercialization focus while also publishing and presenting work in additional tumor settings such as renal cancer. The company has also announced a strategic partnership with Charles River Laboratories to support preclinical oncology studies.